

1 **PREDICTORS FOR PARTICIPATION IN MASS-TREATMENT AND FEMALE GENITAL**  
2 **SCHISTOSOMIASIS RE-INVESTIGATION, AND THE EFFECT OF PRAZIQUANTEL TREATMENT IN**  
3 **SOUTH AFRICAN ADOLESCENTS**

4 **Takalani Girly Nemungadi<sup>1\*</sup>, Elisabeth Klepp<sup>2</sup>, Hashini Nilushika Galappaththi-Arachchige<sup>2</sup>, Pavitra**  
5 **Pillay<sup>3</sup>, Svein Gunnar Gundersen<sup>4</sup>, Birgitte Jyding Vennervald<sup>5</sup>, Patricia D. Ndhlovu<sup>6</sup>, Myra Taylor<sup>1</sup>,**  
6 **Saloshni Naidoo<sup>1</sup>, Eyrun F. Kjetland<sup>1,2</sup>**

7

8 <sup>1</sup>Discipline of Public Health Medicine, College of Health Sciences, University of KwaZulu-Natal,  
9 Durban, South Africa

10 <sup>2</sup> Norwegian Centre for Imported and Tropical Diseases, Oslo University Hospital, Oslo, Norway

11 <sup>3</sup>Department of Biomedical and Clinical Technology, Durban University of Technology, KwaZulu-  
12 Natal, South Africa

13 <sup>4</sup>Institute for Global Development and Planning, University of Agder, Kristiansand, Norway

14 <sup>5</sup>Section for Parasitology and Aquatic Pathobiology, Faculty of Health and Medical Sciences,  
15 University of Copenhagen, Copenhagen, Denmark

16 <sup>6</sup>BRIGHT Academy, Ugu District, South Africa

17

18 \*Corresponding author: Takalani Girly Nemungadi, University of KwaZulu-Natal, School of Nursing  
19 and Public Health, Durban, South Africa, 4041 (Email: takalaninemungadi@gmail.com)

20

**Keywords.** Female genital schistosomiasis; FGS symptoms; homogenous yellow patch; grainy  
sandy patch, mass drug administration, treatment.

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

21

**Type of Article:** Clinical Article

22

## ABSTRACT

### 23 Objective

24 Female Genital Schistosomiasis (FGS) causes intravaginal lesions and symptoms that could be  
25 mistaken for sexually transmitted diseases or cancer. In adults, FGS lesions are refractory to  
26 treatment. The effect of treatment has never been explored in young women; it is unclear if  
27 gynaecological investigation will be possible in this young age group (16 – 23 years). We  
28 explored the predictors for accepting anti-schistosomal treatment and/or gynaecological  
29 reinvestigation in young women, and the effects of anti-schistosomal mass-treatment  
30 (praziquantel) on the clinical manifestations of FGS at an adolescent age.

31

### 32 Method

33 The study was conducted in randomly selected, rural, high schools in Ilembe, uThungulu and  
34 Ugu Districts, KwaZulu-Natal Province, East Coast of South Africa. At baseline, after obtaining  
35 ethical approval and informed consent, gynaecological investigations were conducted in  
36 female learners in grades 8 to 12 (aged 16-23 years). Mass-treatment was offered in the low-  
37 transmission season between May and August (a few in September), in accordance with WHO  
38 recommendations. Reinvestigation was offered after a median of 9 months (range 5-14  
39 months). Univariate, multivariable and logistic regression analysis were used to measure the  
40 association between variables.

41

### 42 Results

43 Of the 2293 learners who came for baseline gynaecological investigations, 1045 (46%) had  
44 signs of schistosomiasis, 209/1045 (20%) had grainy sandy patches; 208/1045 (20%)  
45 homogenous yellow patches; 772/1045 (74%) had abnormal blood vessels; and 404/1045  
46 (39%) were urine positive. Overall, only 26% (587/2293) learners participated in the mass  
47 treatment and 17% (401/2293) participated in the follow up gynaecological reinvestigations.  
48 More than 70% of learners with FGS lesions were lost to follow-up: 156/209 (75%) grainy  
49 sandy patches; 154/208 (74%) homogenous yellow patches; 539/722 (75%) abnormal blood  
50 vessels; 238/404 (23%) urine positive. The grade 12 pupil had left school and did not  
51 participate in the reinvestigations. Amongst those with lesions who came for both treatment  
52 and reinvestigation, 12 (of 19) still had grainy sandy patches, 8 (of 28) had homogenous yellow  
53 patches, and 54 (of 90) had abnormal blood vessels. Only 3 out of 55 remained positive for *S.*  
54 *haematobium* ova. The low mass treatment uptake and huge loss to follow up among those  
55 who had baseline FGS contributed to small sample size at follow up, to understand the effect  
56 of treatment. However, multivariable analysis showed that treatment had effect on the  
57 abnormal blood vessels (adjusted odds ratio = 2.1, 95% CI 1.1 – 3.9 and p 0.018). HIV, current  
58 water contact, water contact as a toddler and urinary schistosomiasis influenced participation  
59 in mass treatment. Grainy sandy patches, abnormal blood vessels, homogenous yellow  
60 patches, previous pregnancy, current water contact, water contact as a toddler and father  
61 present in the family were strongly associated with coming back for follow-up gynaecological  
62 investigation.

63

### 64 Conclusion

65 Compliance to treatment and gynaecological reinvestigation was very low. There is need to  
66 embark on large scale awareness and advocacy in schools and communities before  
67 implementing mass-treatment and investigation studies. Further investigations with large

68 sample size are needed in order to fully understand the effect of treatment on FGS lesions,  
69 including the right timing for treatment.

70

#### 71 AUTHOR SUMMARY

72 Female genital schistosomiasis (FGS) is a neglected tropical disease and it affects many  
73 women and young girls in schistosomiasis endemic areas. A lot of research is still needed to  
74 understand the characteristics of FGS, its prevention, as well as the timing for treatment. As  
75 a result of the limited information, some women who suffer from FGS end up being diagnosed  
76 as suffering from diseases such as human papilloma virus or other sexually transmitted  
77 diseases. The study highlights issues that need to be taken into considerations when providing  
78 treatment or conducting mass treatment for schistosomiasis and FGS or planning  
79 gynaecological investigations to inform FGS control programmes. In this study of adolescent  
80 girls and young women of KwaZulu-Natal Province of South Africa, we sought to explore the  
81 factors that influence participation in mass treatment and gynaecological investigation, and  
82 investigating the effect of praziquantel treatment on FGS. Factors that influenced  
83 participation in mass treatment included HIV, current water contact, water contact as a  
84 toddler and urinary schistosomiasis. Factors that influenced participation in follow up  
85 gynaecological investigation included grainy sandy patches, abnormal blood vessels,  
86 homogenous yellow patches, previous pregnancy, current water contact, water contact as a  
87 toddler and father present in the family. There was low uptake and huge loss to follow up for  
88 mass treatment, and this contributed to small sample size for follow up gynaecological  
89 investigations to understand the effect of treatment. However, multivariable analysis  
90 showed that treatment had effect on the abnormal blood vessels and not on grainy sandy  
91 patches and homogenous yellow patches.

92

93

94

## 95 INTRODUCTION

96 Female Genital Schistosomiasis (FGS) is a complication of schistosomiasis that results from  
97 trapped schistosome eggs, which damage tissues and organs (1,2). It is known to affect  
98 females of all age groups. FGS has a complex disease manifestation spectrum, including  
99 lesions of the cervix and vagina (grainy sandy patches and homogenous yellow patches),  
100 surface bleeding, abnormal blood vessels and rubbery papules (3,4). FGS has also been  
101 associated with sub-fertility or infertility, ectopic pregnancy, spontaneous abortion,  
102 premature birth, and increased susceptibility to HIV transmission and possibly progression.  
103 Reports suggest that eggs are evenly distributed in the genital organs (2,5–7). There are many  
104 case reports of concurrent FGS with cervical intra-epithelial neoplasia and one paper to date  
105 has shown lower Human Papillomavirus (HPV) clearance in FGS positive women or increased  
106 susceptibility to HPV (3,8–12).

107

108 WHO recommends mass drug administration in schistosomiasis endemic schools for  
109 prevention of morbidity, and studies indicate that early treatment may be necessary to  
110 prevent genital lesions in adulthood (13–15). **In South Africa, there is no mass treatment or**  
111 **mass drug administration programme** for schistosomiasis and treatment is case-by-case  
112 upon consultation by the affected individuals. The mass treatment that was conducted  
113 between 1998 and 2001 in KwaZulu-Natal was discontinued due to resource constraints  
114 (16,17). FGS is not known among most health care workers, clinicians and community  
115 members and only approximately 160 gynaecologists were previously informed about FGS in  
116 South Africa (16–19). As a result, FGS is not considered a priority condition. There is therefore  
117 limited data and research and this leads to a low index of suspicion by clinicians and FGS  
118 lesions often being misclassified as sexually transmitted infections or cervical cancer (2,5,20–  
119 27). There have been efforts by authorities in South Africa to mobilise WHO-donated

120 praziquantel in order to implement the mass treatment as per the recommended WHO  
121 strategy over the past years. However, this has been a challenge since, the donated  
122 praziquantel is not registered in the country and is not permitted to be used (28).  
123 Subsequently, treatment has been mobilised from within the country and mass treatment is  
124 being planned for implementation (29). In order to prevent low uptake and to properly plan  
125 for the roll-out of the mass treatment, it is important to identify factors that will influence  
126 participation, and to determine the effect of treatment on FGS symptoms. **It is also important**  
127 **to identify factors that will influence participation in gynaecological investigation in order**  
128 **to improve treatment and other prevention and control measures as well as research**  
129 **information that will provide new knowledge.**

130

131 Between 2011 and 2013, we conducted a follow-up study and sought to explore the feasibility  
132 of the implementation of mass drug administration and gynaecological investigations in  
133 school-going young women in rural KwaZulu-Natal, and to explore the effects on lesions and  
134 symptoms.

## 135 MATERIALS AND METHODS

136 **Ethical considerations.** The study was approved by the Biomedical Research Ethics  
137 Committee (BREC), University of KwaZulu-Natal (Ref BF029/07), KwaZulu-Natal Department  
138 of Health (Reference HRKM010-08) and the Regional Committee for Medical and Health  
139 Research Ethics (REC), South Eastern Norway. The ethical committees were aware that minors  
140 were invited into the study and specifically approved independent minor consent without  
141 parental consent. All study participants were offered anti-schistosomal treatment and, if  
142 applicable, treatment for sexually transmitted diseases, and/or referral to the local health  
143 system for treatment of HIV.

144

145 **Study subjects and area.** The study was conducted between 2011 and 2015 in the KwaZulu-  
146 Natal Province of South Africa. The participants were female learners aged 16 – 23 years, from  
147 randomly selected high schools in Ilembe, uThungulu and Ugu Districts on the East Coast of  
148 South Africa that had not undergone anti-schistosomal mass-treatment before the first  
149 investigation as shown in Table 1. The participants were recruited from schools that were  
150 classified as rural by the South African Department of Basic Education and were below the  
151 altitude of 400 meters above sea level, with an estimated prevalence of *S. haematobium* of  
152 10% or more based on an initial show of hands for red urine in Ugu District and a haematuria  
153 dipstick survey in Ilembe and uThungulu districts (30). Gynaecological examinations were  
154 performed in two research clinics (North of Durban and South of Durban); virgins, pregnant,  
155 and severely ill females were excluded. Schools with prevalence of less than 10% were  
156 excluded

157 **Table 1.** Study design and practicalities, their rationale, and the potential unintended  
 158 consequences

Inclusion considerations	Reason
Participants included were 16 years and above, including Grade 12	<p>In order to explore reversibility of lesions, we wished to invite young women at an earliest possible time for a gynaecological investigation. However, gynaecological investigations are not practically feasible before the age of 16 for cultural, legal and sometimes anatomical reasons (31). Average sexual debut age is 18.7 years in South Africa and many hide sexual debut from e.g. their parents and teachers for as long as they can (32,33).</p> <p>Moreover, some may be worried about the "loss of virginity" during speculum examination (34,35). Visual inspection of the cervix, fornices and vaginal surfaces before sexual debut may therefore be offensive to their sensibilities.</p>
KwaZulu-Natal was chosen as the study area	<p>Firstly, at this tender age, chances were high that these young women would be invited for their first gynaecological examination. Some amongst the pupils might be found to have been raped and a gynaecological examination might trigger psychological reactions. Therefore, we looked for a study area where psychologists and support centres would be available for study participants in a schistosomiasis endemic area.</p> <p>Secondly, there are more than 4,000 rural schools in KZN and we estimated that we would be able to reach the necessary sample size (36,37).</p>
Although some young women with multiple lesions were treated at the clinic, most were not done immediately after examination at the clinic.	<p>Treatment with praziquantel was done at schools, not at the research clinics for the following reasons:</p> <ol style="list-style-type: none"> <li>1) Mass Drug Administration is recommended so that siblings and class mates are treated simultaneously (15)</li> <li>2) Anti-schistosomal treatment with Praziquantel should be given in the low-transmission season (28,38)</li> <li>3) Praziquantel may cause nausea and sometimes vomiting; if treatment had been done at clinic immediately after investigation, some learners might become car sick on the way from the clinic, it could potentially scare others from participating (15).</li> </ol>

159  
 160

161 **Questionnaires and clinical examinations.** Group information, individual information and the  
 162 consent form procedure was done at the school over a 2-week-period. Consent forms and  
 163 parent information were distributed in advance (39–41). The investigation has been described  
 164 previously. Briefly, a questionnaire on water contact, reproductive history, genital and  
 165 abdominal symptoms was administered individually to participants in isiZulu (the local  
 166 language) prior to gynaecological examination (30). Teachers would suggest days when it  
 167 would be suitable to fetch learners from schools to go to the research clinic. Teenagers had  
 168 indicated they were embarrassed to give urine in school so urine was collected only while



169 they were at the clinic. On pre-reserved days, a female driver, trained and well-informed  
170 about the study, would pick up 4-13 participants (depending on the vehicle size) for the drive  
171 to the clinic for gynaecological examinations.

172

173 **Treatment.** In accordance with the WHO policy for areas of high schistosomiasis endemicity,  
174 mass treatment of participants and other learners in enrolled schools was carried out during  
175 the winter season (low-transmission season) after the baseline gynaecological examination.  
176 Treatment began after lunch to ensure that the children had eaten their free school lunches  
177 before treatment and to save the costs on food for the programme. Depending on the size of  
178 school, the treatment team comprised of 2-4 nurses and 2-4 assistants (27). Bread and  
179 bananas were distributed to learners who had not received a school lunch. Learners with  
180 signed consent forms were weighed, and the number of praziquantel tablets was calculated  
181 for the dose of 40 mg per kg of body weight. As described previously, a designated nurse  
182 directly observed all tablet ingestion by counting the number of tablets in each learner's hand  
183 and watching for hand-to-mouth intake (27). The treatment team stayed in the school for an  
184 hour after the last dose to allow learners to report any side effects. All learners, even the  
185 untreated, were allowed to come back for follow-up gynaecological examination.

186

187 **Sample size calculation and statistical analyses.** Demographic and clinical variables were  
188 explored as predictors for (1) participation in mass-treatment and (2) returning to a follow-  
189 up gynaecological investigation. We planned a study of independent cases and controls with  
190 3 control(s) per case. Prior data indicated that the probability of coming back for a  
191 gynaecological investigation among those with FGS disease is 15%. If the true probability of  
192 FGS among those who do not return is 9%, we will need to study 318 FGS patients and 954  
193 without FGS to be able to reject the null hypothesis that the exposure rates for the groups

194 are equal with probability (power) 80%. The Type I error probability associated with this test  
195 of this null hypothesis is 0.05. We will use an uncorrected chi-squared statistic to evaluate  
196 this null hypothesis.

197

198 In order to study simultaneously the impact of several variables, logistic regression analysis  
199 was applied with a 5% significance level; as a general rule variables were included if the p-  
200 value from the crude association was less than 0.2 and if the Spearman rank correlation  
201 coefficient was below 0.7. Age was forced into the model.

202

203 To assess the overlap of the FGS lesions among the learners, we created Venn diagrams using  
204 Venny version 2.1 (Juan Carlos Oliveros,  
205 <https://bioinfogp.cnb.csic.es/tools/venny/index2.0.2.html>)


206

207 RESULTS

208 **Description of the study population.**

209 A total of 2293 adolescent girls and young women from 70 secondary schools were enrolled and  
210 examined gynaecologically for FGS lesions at baseline. As shown in Figure 1, 1045/2293 (46%) learners  
211 had genital lesions or signs of urinary schistosomiasis at baseline. None of them had rubbery papules.  
212 Abnormal blood vessels were the most common findings.

213




214

215 Figure 1. Genital lesions and signs for schistosomiasis amongst adolescent girls and young  
216 women in Kwa-Zulu-Natal between 2012 and 2013.

217

218 As shown in Figure 2, 271 learners had more than one FGS lesions while 556 had only one FGS  
219 lesion (ABV: abnormal blood vessels, GSP: grainy sandy patches, HYP: homogenous yellow  
220 patches).

221



222

223 Figure 2. Venn diagram showing an overlap of baseline FGS lesions among learners.

224

### 225 **Mass treatment participation**

226 Treatment with praziquantel (40mg/kg) was given in the low-transmission season (South  
227 African winter between May and August, including a few in September). Only 26% (587 of the  
228 2293) learners were treated between baseline and follow-up. Multivariable analysis showed  
229 that HIV, current water contact, water contact as a toddler and urinary schistosomiasis  
230 positively influenced learners' willingness to participate in the mass treatment (Table 2). A  
231 greater loss to follow-up for mass treatment was observed in the Southern research clinic as  
232 compared to the Northern clinic (odds ratio = 2.1, 95% CI 1.7 – 2.6 and  $p < 0.001$ ).

233

234

235

Table 2. Underlying factors and compliance with mass-treatment

History	Participated in mass treatment (%)	Did not participate in mass treatment (%)	Univariate analysis			Multivariable analysis		
			Odds ratio	95% Confidence Interval	p-value	Adjusted odds ratio	95% Confidence Interval	p-value
Grade 8	4/209 (2)	6/1026 (1)	1			1		
Grade 9	13/209 (6)	43/1026 (4)	0.9	0.3-2.6	0.913	0.7	0.2-2.3	0.600
Grade 10	51/209 (24)	277/1026 (27)	0.6	0.2-1.5	0.274	0.4	0.2-1.2	0.113
Grade 11	128/209 (61)	507/1026 (49)	0.6	0.3-1.7	0.389	0.5	0.2-1.5	0.249
Grade 12	13/209 (6)	193/1026 (189)	0.9	0.3-2.3	0.813	0.6	0.2-0.7	0.346
Current water contact	391/587 (59)	596/1050 (57)	1.5	1.2 – 1.9	<0.001	1.4	0.1-1.8	0.003
Urinary schistosomiasis	90/517 (17)	193/895 (22)	0.8	0.6 – 1.0	0.060	0.7	0.5-0.9	0.037
Abnormal blood vessels	215/587 (37)	337/1050 (32)	1.2	0.9 – 1.5	0.063	1.1	0.8-1.3	0.680 <sup>a</sup>
						1.1	0.9-1.4	0.245 <sup>b</sup>
Water contact as toddler	339/587 (58)	611/1050 (58)	1.5	1.2 – 1.9	<0.001	1.4	1.1-1.8	0.002
HIV	86/555 (15)	210/999 (21)	0.7	0.5 – 0.9	0.008	0.7	0.5-0.9	0.015
Red urine previously or now	155/587 (26)	320/1045 (31)	0.8	0.6 – 1.0	0.072	0.8	0.7-1.1	0.138
Mother present in the family	375/587 (64)	625/1045 (60)	1.2	0.9 – 1.5	0.105	1.3	0.9-1.6	0.055
Homogenous yellow patch	60/587 (10)	90/1050 (09)	1.2	0.9 – 1.7	0.267			
Has ever been pregnant	280/587 (48)	504/1050 (48)	0.9	0.8 – 1.2	0.907			
Heavy bleeding with clots	176/408 (43)	350/755 (46)	0.9	0.7 – 1.1	0.292			
Father present in the family	136/587 (23)	251/1045 (24)	0.9	0.8 – 1.2	0.698			
Genital itch	361/587 (61)	658/1046 (63)	0.9	0.8 – 1.2	0.573			
Genital burn	243/587 (41)	464/1046 (44)	0.9	0.7 – 1.1	0.246			
Genital sore/ulcer	114/585 (19)	206/1043 (20)	0.9	0.8 – 1.3	0.898			
Genital lump	93/583 (16)	176/1038 (17)	0.9	0.7 – 1.2	0.602			
Urge with leak	270/587 (46)	499/1045 (48)	0.9	0.8 – 1.1	0.496			
Urge	202/585 (35)	346/1044 (33)	1.1	0.9 – 1.3	0.569			
Dysuria	297/587 (35)	550/1044 (52)	0.9	0.8 – 1.1	0.418			
Bloody discharge	104/583 (17)	198/1043 (19)	0.9	0.7 – 1.2	0.569			
Watery discharge	369/583 (63)	638/1039 (61)	1.1	0.9 – 1.3	0.452			
Abnormal discharge smell	260/583 (45)	490/1042 (47)	0.9	0.7 – 1.1	0.346			
<b>Grainy sandy patch</b>	49/587 (08)	102/1050 (08)	0.8	0.6 – 1.2	0.359			

<sup>a</sup>multivariable with abnormal blood vessels and current water contact, <sup>b</sup>multivariable with abnormal blood vessels and water contact as a toddler.

## 236 Gynaecological reinvestigation

237 Table 3 shows that a total of 709 learners (31% of the 2293 learners) were interviewed at  
 238 follow up. Of the 709, 398 agreed to participate in the follow up gynaecological investigation;  
 239 the majority (32%) felt that they were not ready. The willing participants were reinvestigated  
 240 after a median of 9 months (range 5 - 14 months). The median age of those followed-up was  
 241 19 years (range 16 - 23 years), and those who were lost to follow-up had a median age of 18  
 242 years (range 16 – 23 years).

243

244 Table 3. Reasons for refusing follow up gynaecological examination (n=709)

Reasons for denying or aborting gynaecological examination	Came for follow up		Total (%)
	No (%)	Yes (%)	
Did not deny or abort	16 (3.9)	398 (%)	414 (100)
Fear	26 (100)	0 (0)	26 (100)
Not ready	127 (100)	0 (0)	127 (100)
Menstruation	24 (92)	2 (8)	26 (100)
Virgin	14 (100)	0 (0)	14 (100)
Pregnant	53 (100)	0 (0)	53 (100)
Other	48 (98)	1 (2)	49 (100)
<b>TOTAL</b>	<b>308 (43)</b>	<b>401 (57)</b>	<b>709 (100)</b>

245

246 Table 4 show factors that may have contributed to compliance with follow up gynaecological  
 247 investigation. The three FGS lesions (grainy sandy patches, abnormal blood vessels and  
 248 homogenous yellow patches), previous pregnancy, current water contact, water contact as a  
 249 toddler and father present in the family were strongly associated with coming back for a  
 250 follow-up investigation in both univariate and multivariable analysis. Multivariable analysis of  
 251 the three FGS lesions individually (to account for a causal relationship) with current water  
 252 contact, previous pregnancy and water contact as a toddler had no effect on the association.  
 253 A greater loss to follow-up for gynaecological investigation was observed in the Southern  
 254 research clinic as compared to the Northern clinic (odds ratio = 1.9, 95% CI 1.5 – 2.4 and p  
 255 <0.001).


Table 4. Underlying factors associated with coming back for follow-up gynaecological investigations

History	Came for follow-up (%)	Did not come for gynaecological investigation	Univariate analysis			Multivariable analysis		
			Odds ratio	95% Confidence Interval	p-value	Adjusted odds ratio	95% Confidence Interval	p-value
Grade 8	5/400 (1)	18/1863 (1)	1			1		
Grade 9	24/400 (7)	92/1863 (5)	0.9	0.3-2.8	0.910	0.8	0.3-2.5	0.724
Grade 10	120/400 (30)	488/1863 (26)	0.9	0.3-2.4	0.813	0.8	0.3-2.2	0.635
Grade 11	214/400 (54)	742/1863 (40)	1.0	0.4-2.8	0.941	0.9	0.3-2.5	0.803
Grade 12	37/330(6)	523/1863 (28)	0.3	0.1-0.7	0.010	0.2	0.1-0.6	0.004
Grainy sandy patch*	56/401 (14)	153/1892 (8)	1.8	1.3-2.6	<0.001	1.8	1.3-2.6	<0.001
Abnormal blood vessels*	185/401 (46)	537/1892 (28)	2.3	1.7-2.7	<0.001	2.2	1.7-2.7	<0.001
Homogenous yellow patch*	55/401 (14)	153/1892 (8)	1.8	1.3-2.5	<0.001	1.8	1.3-2.5	0.001
Has ever been pregnant	236/401 (60)	838/1892 (44)	1.8	1.4-2.2	<0.001	1.8	1.5-2.3	<0.001
Water contact as toddler	260/401 (65)	1119/1892 (59)	1.3	1.0-1.6	<0.034	1.4	1.1-1.7	0.009
Current water contact	257/401 (64)	1124/1892 (59)	1.2	0.9 - 1.5	0.082	1.4	1.1-1.7	0.012
Red urine previously or now	110/398 (28)	571/1883 (30)	0.9	0.7 – 1.1	0.287	0.8	0.6-1.1	0.140
Father present in the family	71/398 (19)	454/1881 (24)	0.7	0.5 – 0.9	0.007	0.7	0.5-0.9	0.010
Genital lump	65/394 (17)	311/1872 (17)	0.9	0.7 – 1.3	0.955			
Condom use	130/319 (41)	649/1604 (41)	1.0	0.8 – 1.3	0.923			
Heavy bleeding with clots	113/259 (44)	628/1403 (45)	0.9	0.7 – 1.2	0.736			
HIV	83/386 (22)	356/1794 (20)	1.1	0.8 – 1.4	0.461			
Mother present in the family	231/399 (58)	1136/1880 (60)	0.9	0.7 – 1.1	0.349			
Genital itch	253/399 (63)	1155/1884 (61)	1.1	0.9 – 1.4	0.433			
Genital burn	179/399 (45)	809/1884 (43)	1.1	0.9– 1.3	0.482			
Genital sore/ulcer	77/398 (19)	347/1879 (19)	1.1	0.8 – 1.4	0.682			
Urge with leak (urgenic1)	200/398 (50)	882/1883 (47)	1.1	0.9 – 1.4	0.216			
Urge but no leak (urge1)	137/392 (35)	639/1881 (34)	1.0	0.8 – 1.3	0.837			
Dysuria	217/398 (55)	982/1882 (52)	1.1	0.9 – 1.4	0.395			
Bloody discharge	70/397 (18)	356/1875 (19)	0.9	0.7 – 1.2	0.530			
Watery discharge	252/396 (64)	1168/1872 (62)	1.1	0.8 – 1.3	0.642			
Abnormal discharge smell	179/399 (45)	878/1869 (47)	0.9	0.7 – 1.1	0.442			
<b>Urinary schistosomiasis</b>	82/367 (22)	322/1579 (20)	1.1	0.9 – 1.5	0.407			

\*Were analysed separately because some participants were affected by more than one lesion and there may be causal relationship between the three FGS lesions.

256 On the baseline investigation day, participants were informed about genital lesions (grainy sandy  
 257 patches, homogenous yellow patched and abnormal blood vessels) but urine microscopy results  
 258 were not readily available as the laboratory investigation were still going on. However, only  
 259 approximately 25% of the young women with lesions returned for follow-up examinations (Figure  
 260 3, bold frame). As shown in Figure 3 (hatched frame), more than 70% of learners that had genital  
 261 lesions or signs of FGS at baseline were lost to follow up for gynaecological investigation, and 23%  
 262 of learners with urinary schistosomiasis were lost to follow-up.

263



264

265 Figure 3. Follow-up amongst adolescent girls and young women investigated for Female Genital  
 266 Schistosomiasis in Kwa-Zulu-Natal.

267 Legend:

268 Hatched frame: lost to follow-up for gynaecological investigation.

269 Bold frame: Remaining findings at follow-up gynaecological investigation

270



271 **The effect of treatment**

272

273 Multivariable analysis of the effect of treatment on baseline FGS showed that treatment only  
 274 had an effect on the abnormal blood vessels (adjusted odds ratio = 2.1, 95% CI 1.1 – 3.9 and  
 275 p 0.018) (Table 5). Treatment was protective against urinary schistosomiasis; only 3 learners  
 276 among the 55 that were treated remained positive for urinary schistosomiasis at follow up  
 277 (adjusted odds ratio = 0.4, 95% CI 0.01 – 0.1 and p < 0.001).

278

279 Before accounting for FGS lesions at baseline (including those with and without FGS lesions  
 280 at baseline), the univariate analysis showed a strong association between treatment and two  
 281 FGS lesions (homogenous yellow patches and abnormal blood vessels); at multivariable  
 282 analysis this association remained unchanged for the abnormal blood vessels (adjusted odds  
 283 ratio = 2.3, 95% CI 1.5 – 3.6 and p <0.001) (Table 5) whereas it became insignificant for  
 284 homogenous yellow patches.

285

286 Table 5. Effect of treatment - remaining FGS lesions among the treated and untreated

FGS lesions	Treated (%)	Untreated (%)	Univariate analysis			Multivariable analysis		
			OR	95% CI	p-value	AOR	95% CI	p-value
<b>Effect of treatment among those with FGS a baseline</b>								
Grainy sandy patches	12/19 (63)	23/34 (68)	0.8	0.3 – 2.7	0.741	0.5	1.1 – 2.1	0.369
Homogenous yellow patches	08/28 (29)	03/26 (12)	3.1	0.7 – 3.2	0.120	6.7	0.9 - 48	0.058
Abnormal blood vessels	54/90 (60)	40/93 (43)	1.9	1.1 – 3.6	0.022	2.1	1.1 – 3.9	0.018
Urinary schistosomiasis	3/55 (5)	73/183 (53)	0.5	0.02 - 0.2	<0.001	0.4	0.01 – 0.1	<0.001
<b>Overall FGS rate at follow up (after treatment and including FGS among those who did not have FGS at baseline)</b>								
Grainy sandy patches	25/167 (15)	35/229 (15)	0.9	0.6 – 1.7	0.931	0.9	0.5 – 1.7	0.903
Homogenous yellow patches	24/167 (14)	17/229 (07)	2.1	1.1 – 4.0	0.025	1.8	0.9 – 3.5	0.096
Abnormal blood vessels	81/167 (49)	66/229 (29)	2.3	1.5 – 3.5	<0.001	2.3	1.5 – 3.6	<0.001
Urinary schistosomiasis	07/351 (02)	91/681 (13)	0.1	0.1 – 0.3	<0.001	0.1	0.1 – 0.3	<0.001

287

## 288 DISCUSSION

289 The abnormal blood vessels were refractory to praziquantel treatment. Abnormal blood  
290 vessels and grainy sandy patches were previously found to be significantly associated with  
291 the presence of live worms as opposed to the homogenous yellow patches (42). The  
292 association between praziquantel treatment and abnormal blood vessels may be an  
293 indication that abnormal blood vessels are an early stage of the grainy sandy patches and are  
294 easy to eliminate as opposed to the grainy sandy patches and homogenous yellow patches. It  
295 is important to note that different investigators define the investigation findings differently  
296 and that the investigators of gynaecological examinations were different in baseline and  
297 follow-up studies.

298

299 South Africa is not implementing mass drug administration (43); the remaining gynaecological  
300 symptoms among the treated were high and may be an indication that for effectiveness,  
301 several rounds of treatment are required and should be started at an earlier age. This  
302 supports findings in Zimbabwe where a standard single-dose of praziquantel did not have  
303 effect on the inflammatory lesions of FGS that had formed and developed over a few years  
304 (13). The timing for follow up investigations may have been too soon for some learners to  
305 determine the true effect of treatment (the median time period between praziquantel  
306 (40mg/kg) treatment and reinvestigation was 5 months (range 5 – 14 months).

307

308 Treatment with praziquantel is the only recommended effective way of killing adult helminths  
309 and mature live eggs, but has no effect on the calcified ova; early treatment is therefore  
310 crucial before the ova are deposited in the tissue and cause damage (6,44). This may possibly  
311 explain the remaining gynaecological symptoms among the treated, including those who did

312 not have the lesions at baseline. A retrospective study found that treatment at an early age  
313 seems to prevent gynaecologic morbidity (13).

314

315 Lack of a regular mass treatment programmes in South Africa, repeated exposure to risky  
316 water, and re-infections could have led to continuous FGS lesions even after a single dose of  
317 praziquantel. Further investigations and follow up studies are therefore needed in countries  
318 that are implementing mass drug administration and areas that are not implementing mass  
319 drug administration. These studies will help with information to fully understand the  
320 differences between the FGS lesions and whether praziquantel treatment can eliminate these  
321 lesions, including the right timing to possibly eliminate the lesions. Currently, only one study  
322 has investigated the impact of treatment on gynaecological lesions and found no significant  
323 change in the adult sandy patches and contact bleeding over a 12-month period, even though  
324 urinary egg excretion ceased (45). Another study found that schistosomiasis PCR remained  
325 positive in the genitals after treatment (46). The lack of information and complexity in  
326 conducting research on how long it takes for the FGS lesions to manifest following infection  
327 made it difficult to determine whether the FGS lesions diagnosed at follow-up were due to  
328 schistosomiasis re-infection or were progressive lesions that had not yet manifested and  
329 therefore diagnosed at baseline. Lack of a regular mass treatment programme in South Africa,  
330 repeated exposure to risky water, and re-infections could have led to continuous FGS lesions  
331 even after a single dose of praziquantel.

332

333 Identification of HIV, current water contact, water contact as a toddler and urinary  
334 schistosomiasis as factors that influenced learners to participate in mass treatment are in  
335 consistent with the general knowledge of the impact of these factors on schistosomiasis i.e.  
336 schistosomiasis as a risk factor for HIV, and water contact as a risk for schistosomiasis. The

337 pre-treatment health education may have played a role in influencing these participants to  
338 accept the treatment. Learners who felt they do not have a problem with these identified  
339 factors may have perceived it unnecessary for them to get treated. Furthermore, the three  
340 FGS lesions (grainy sandy patches, abnormal blood vessels and homogenous yellow patches),  
341 previous pregnancy, current water contact, water contact as a toddler and father present in  
342 the family were strongly associated with returning for follow-up investigation. It is anticipated  
343 that the investigators at the Northern clinic had gained more experience in both health  
344 education and community engagement as opposed to when they conducted investigations at  
345 the Southern clinic (the 1<sup>st</sup> investigation site) where there was a greater loss to follow up.  
346 Therefore, active ongoing community engagement targeting both learners, parents and the  
347 entire community at risk is crucial in order to empower the community with the full  
348 knowledge on prevention and control that will enable them to make informed decisions.

349

350 South Africa is endemic for schistosomiasis with some focal areas having high and moderate  
351 infections (42), and FGS studies among the young population may help identify targeted  
352 interventions. Study findings revealed that more than 20% of the adolescent women in  
353 KwaZulu-Natal province had three well-known genital mucosal manifestations of FGS (30); in  
354 Limpopo Province, FGS accounted for 87.6% of the female cases in a study that described the  
355 pathology of biopsy diagnosed schistosomiasis (47). However, treatment in South Africa is still  
356 case-based and, as in many other countries, most community members do not seek early  
357 treatment or do not seek treatment at all (17,27,48). Therefore, those infected and those that  
358 complicate to FGS remain infected or with FGS complication; some individuals are  
359 misdiagnosed as sexually transmitted infections (STIs) or cervical cancer (2,5,20–27). In this  
360 study, loss to follow up was a major challenge. Involving community health workers in FGS  
361 studies may assist with managing those who are lost to follow up because it would be easier

362 for them to maintain contact and follow up with the learners in their catchment area,  
363 especially those found to have FGS symptoms.

364

365 It is important to note that gynaecological examination was not possible among the early and  
366 middle adolescent group due to virginity, fear, pregnancy, and privacy and other related  
367 issues. Early adolescence and some middle adolescence may only be targeted for prevention  
368 and only examined at the late adolescence stage to check if they developed any FGS after  
369 repeated treatment. Observational studies in young adolescents and adults are critical in  
370 determining the effect of early treatment on schistosomiasis and FGS. It is similarly important  
371 to determine the burden of infertility among those living in endemic areas and determine the  
372 association with FGS. Therefore, it is important for countries such as South Africa to establish  
373 mass drug administration programmes in order to prevent sustained infections that can lead  
374 to FGS.

375

376 The high loss to follow up is worrying because more knowledge is required through research  
377 to understand FGS pathogenesis and improve the knowledge of clinicians. For instance, it is  
378 important to note that the high loss to follow during mass treatment in this study contributed  
379 to small sample size to determine the effect of treatment on FGS. Currently, the lack of  
380 knowledge of FGS among most clinicians and affected communities is concerning due to the  
381 reported high prevalence of genital lesions (49). It has been reported that up to 75% of all  
382 women and girls infected with urinary *S. haematobium* have lesions in the uterus, cervix,  
383 vagina or vulva (4). Many women have been reported to have genital schistosomiasis without  
384 urinary excretion of *S. haematobium* eggs (2,4,13,50,51). In sub-Saharan Africa, it is estimated  
385 that 56 million women have FGS (2).

386

387 In addition to the identified unintended consequences due to inclusion criteria and research  
388 actions reported under results, the high loss to follow-up and low treatment coverage in this  
389 study could also be attributed to factors that were reported by another study in South Africa  
390 in Ugu District of KwaZulu-Natal Province. This Ugu District study was conducted among grade  
391 10 – 12 learners, teachers, community health workers and traditional healers (16,17). Factors  
392 that contributed to low coverage in this Ugu District study were reported to be:

- 393 • older age group;
- 394 • lack of knowledge;
- 395 • attending a large school
- 396 • parental control and a closer teacher follow-up in younger children and in small  
397 schools;
- 398 • misconceptions that schistosomiasis is a self-healing disease and symptoms confused  
399 with sexually transmitted infections;
- 400 • the chronicity of the disease is not known to the general population;
- 401 • teasing and stigma;
- 402 • schistosomiasis-related absenteeism that may reach 30% on some days;
- 403 • tablets must be distributed by health professionals in South Africa;
- 404 • schools reluctant to provide more than one day for treatment in order to minimise  
405 disturbance (15,17,27).

406 The lower loss to follow up at the North of Durban clinic may be attributed to the experience  
407 gained while operation at the first clinic (South of Durban). A praziquantel mass treatment  
408 programme was implemented in South Africa, in Ugu District of KwaZulu-Natal Province  
409 between 1998 and 2001 among grade 10 – 12 learners, teachers, community health workers  
410 and traditional healers, and only reached 44% of the learners instead of the WHO and the

411 South African National Department of Health recommended target of 75% coverage (27). This  
412 shows a need to embark on large scale awareness and advocacy campaign in schools and  
413 communities, coordinated by the Department of Health and in collaboration with the  
414 Department of Basic Education, non-governmental organisations and community leaders,  
415 before implementing FGS studies among young people and mass treatment administration,  
416 to improve participation in research that will inform control measures.

417

418 Study limitations include the small sample size to determine the effect of treatment due to  
419 low treatment coverage and loss to follow up. Another limitation was that treatment was not  
420 done immediately after baseline, and therefore many learners were not treated between  
421 baseline and follow up either due to factors described above by Lothe *et al* in the qualitative  
422 studies in Ugu District, KwaZulu-Natal Province (16,17). As a result, some learners that were  
423 not treated between baseline and follow up were only treated during follow-up. Some of the  
424 learners under 16 years might already have had chronic lesions, and inclusion of the Grade 12  
425 learners could have contributed to loss to follow up because of those who passed matric and  
426 moved to tertiary institutions the following year.

427

428 In summary, it is critical to conduct vigorous ongoing community engagements for awareness  
429 and buy-in prior to mass treatment and gynaecological investigations in order to improve  
430 community participation. Because of the small sample size due to loss to follow-up, it is  
431 difficult to draw firm conclusions about the effect of treatment on FGS lesions.

432

433

434

436 AUTHOR CONTRIBUTION

437

438 **Takalani Girly Nemungadi** conceived the presented idea, carried out the laboratory and statistical  
439 analysis, contributed to the writing and finalisation of the manuscript

440 **Eyrun F. Kjetland** helped conceive the presented idea, supervised the project, carried out statistical  
441 analysis, contributed to the writing and finalisation of the manuscript

442 **Saloshni Naidoo** helped supervise the project and contributed to writing

443 **Elisabeth Kleppa** contributed to conceptualisation and writing

444 **Hashini Nilushika Galappaththi-Arachchige** contributed to conceptualisation and writing

445 **Pavitra Pillay** contributed to conceptualisation and writing

446 **Svein Gunnar Gundersen** contributed to conceptualisation and writing

447 **Birgitte Jyding Vennervald** contributed to conceptualisation and writing

448 **Patricia Ndhlovu** contributed to conceptualisation and writing

449 **Myra Taylor** contributed to conceptualisation and writing

450

451 ACKNOWLEDGMENTS

452 We are appreciative of the support from Roy Manyaira, Silindile Gagai and other staff at  
453 BRIGHT Research in KwaZulu-Natal, South Africa. We thank all the girls and young women  
454 who participated in the study.

455

CONFLICTS OF INTEREST

456 All authors report no conflicts of interest.

457



## REFERENCES

- 458 1. Hegertun IEA, Sulheim Gundersen KM, Kleppa E, Zulu SG, Gundersen SG, Taylor  
459 M, et al. *S. haematobium* as a Common Cause of Genital Morbidity in Girls: A Cross-  
460 sectional Study of Children in South Africa. *PLoS Negl Trop Dis*. 2013;7(3):e2104 (1-  
461 8).
- 462 2. UNAIDS, World Health Organization. No more neglect. Female genital  
463 schistosomiasis and HIV. Integrating reproductive health interventions to improve  
464 women's lives [Internet]. Geneva, Switzerland; 2019 [cited 2020 Mar 12]. Available  
465 from:  
466 [https://www.unaids.org/sites/default/files/media\\_asset/female\\_genital\\_schistosomiasis](https://www.unaids.org/sites/default/files/media_asset/female_genital_schistosomiasis_and_hiv_en.pdf)  
467 [\\_and\\_hiv\\_en.pdf](https://www.unaids.org/sites/default/files/media_asset/female_genital_schistosomiasis_and_hiv_en.pdf)
- 468 3. Kjetland EF, Norseth HM, Taylor M, Lillebø K, Kleppa E, Holmen SD, et al.  
469 Classification of the lesions observed in female genital schistosomiasis. *Int J Gynaecol*  
470 *Obstet* [Internet]. 2014;127:227–8. Available from:  
471 [http://www.scopus.com/inward/record.url?eid=2-s2.0-](http://www.scopus.com/inward/record.url?eid=2-s2.0-84906529324&partnerID=MN8TOARS)  
472 [84906529324&partnerID=MN8TOARS](http://www.scopus.com/inward/record.url?eid=2-s2.0-84906529324&partnerID=MN8TOARS)
- 473 4. Kjetland EF, Gwanzura F, Ndhlovu PD, Mduluza T, Gomo E, Mason PR, et al. Simple  
474 clinical manifestations of genital *Schistosoma haematobium* infection in rural  
475 Zimbabwean women. *Am J Trop Med Hyg* [Internet]. 2005 Mar;72(3):311–9.  
476 Available from: <http://www.ncbi.nlm.nih.gov/pubmed/15772328>
- 477 5. Christinet V, Lazdins-Helds JK, Stothard JR, Reinhard-Rupp J. Female genital  
478 schistosomiasis (FGS): from case reports to a call for concerted action against this  
479 neglected gynaecological disease. *Int J Parasitol*. 2016 Jun 1;46(7):395–404.
- 480 6. World Health Organisation. Ending the neglect to attain the Sustainable Development  
481 Goals: A road map for neglected tropical diseases 2021–2030. Geneva, Switzerland:  
482 World Health Organisation; 2020. 1–196 p.
- 483 7. Kjetland EF, Leutscher PDC, Ndhlovu PD. A review of female genital  
484 schistosomiasis. *Trends Parasitol* [Internet]. 2012;28(2):58–65. Available from:  
485 <http://www.ncbi.nlm.nih.gov/pubmed/22245065>
- 486 8. Eustace D, Trehan A, Raju KS, Derias N, Pambakian H. Abdominal pain and vaginal  
487 bleeding associated with schistosomiasis of the genital tract. *J Obstet Gynaecol*  
488 (Lahore) [Internet]. 2009;12(6):427–8. Available from:  
489 <https://doi.org/10.3109/01443619209025953>
- 490 9. Alalade AO, Leeson SC, Andrady U. An unusual association: Vulval schistosomiasis,  
491 microinvasive vulval squamous cell carcinoma and high-grade vulval intraepithelial  
492 neoplasia in HIV patient. *Gynecol Surg*. 2009;6(2):177–9.
- 493 10. Kjetland EF, Ndhlovu PD, Mduluza T, Deschoolmeester V, Midzi N, Gomo E, et al.  
494 The effects of genital *Schistosoma haematobium* on human papillomavirus and the  
495 development of neoplasia after 5 years in a Zimbabwean population. A pilot study. *Eur*  
496 *J Gynec Oncol* [Internet]. 2010/06/10. 2010;31(2):169–73. Available from:  
497 [http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Cit](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=20527233)  
498 [ation&list\\_uids=20527233](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=20527233)
- 499 11. Lalaina N, Irène RZ, Patrick M, Gabriël RP, Soa R. Schistosomiasis with Cervical  
500 Cancer: About 2 Cases and Literature Review. *Open J Pathol*. 2021;11(01):1–6.
- 501 12. Kutz JM, Rausche P, Rasamoelina T, Ratefiarisoa S, Razafindrakoto R, Klein P, et al.  
502 Female genital schistosomiasis, human papilloma virus infection, and cervical cancer  
503 in rural Madagascar: a cross sectional study. *Infect Dis poverty* [Internet].  
504 2023;12(1):89. Available from: <https://doi.org/10.1186/s40249-023-01139-3>
- 505 13. Kjetland EF, Ndhlovu PD, Kurewa EN, Midzi N, Gomo E, Mduluza T, et al.  
506 Prevention of gynecologic contact bleeding and genital sandy patches by childhood  
507 anti-schistosomal treatment. *Am J Trop Med Hyg* [Internet]. 2008/07/09. 2008

- 508 Jul;79(1):79–83. Available from:  
509 <http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Cit>  
510 [ation&list\\_uids=18606767](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Cit&list_uids=18606767)
- 511 14. World Health Organisation. Deworming adolescent girls and women of reproductive  
512 age: Policy brief [Internet]. 2021. Available from:  
513 <https://www.who.int/publications/i/item/9789240037670>
- 514 15. World Health Organization. Helminth control in school-age children: A guide for  
515 managers of control programmes. 2011.
- 516 16. Lothe A, Oyhus AO. Treating Bilharzia among High School Pupils. A study of  
517 opportunities and constraints for treating Bilharzia among high school pupils in Ugu  
518 district, South Africa. Vol. Masters, Faculty of Economics and Social Sciences.  
519 [Development Management]: Agder University College; 2012.
- 520 17. Lothe A, Zulu N, Øyhus AO, Kjetland EF, Taylor M. Treating schistosomiasis among  
521 South African high school pupils in an endemic area, a qualitative study. *BMC Infect*  
522 *Dis*. 2018;18(1):1–10.
- 523 18. Kukula VA, MacPherson EE, Tsey IH, Stothard JR, Theobald S, Gyapong M. A major  
524 hurdle in the elimination of urogenital schistosomiasis revealed: Identifying key gaps  
525 in knowledge and understanding of female genital schistosomiasis within communities  
526 and local health workers. Hsieh MH, editor. *PLoS Negl Trop Dis* [Internet]. 2019 Mar  
527 21 [cited 2019 Apr 2];13(3):e0007207. Available from:  
528 <http://dx.plos.org/10.1371/journal.pntd.0007207>
- 529 19. Sommerfelt I, Ndhlovu P, Taylor M, Naidoo S, Pillay P, Haaland H, et al. Health  
530 professionals’ knowledge about female genital schistosomiasis. A qualitative  
531 investigation in a schistosomiasis endemic area in South Africa. *SSM - Qual Res Heal*  
532 [Internet]. 2023 Jun 1 [cited 2023 Jun 26];3:100292. Available from:  
533 <https://linkinghub.elsevier.com/retrieve/pii/S2667321523000768>
- 534 20. Toller A, Scopin AC, Apfel V, Prigenzi KC, Tso FK, Focchi GR, et al. An interesting  
535 finding in the uterine cervix: *Schistosoma hematobium* calcified eggs. *Autops Case*  
536 *Rep* [Internet]. 2015/10/21. 2015;5(2):41–4. Available from:  
537 <http://www.ncbi.nlm.nih.gov/pubmed/26484333>
- 538 21. Mazigo HD, Samson A, Lambert VJ, Kosia AL, Ngoma DD, Murphy R, et al. “We  
539 know about schistosomiasis but we know nothing about FGS”: A qualitative  
540 assessment of knowledge gaps about female genital schistosomiasis among  
541 communities living in *Schistosoma haematobium* endemic districts of Zanzibar and  
542 Northwestern Tanzania. Knopp S, editor. *PLoS Negl Trop Dis* [Internet]. 2021 Sep 30  
543 [cited 2021 Oct 4];15(9):e0009789. Available from:  
544 <https://journals.plos.org/plosntds/article?id=10.1371/journal.pntd.0009789>
- 545 22. Engels D, Hotez PJ, Ducker C, Gyapong M, Bustinduy AL, Secor WE, et al.  
546 Integration of prevention and control measures for female genital schistosomiasis, HIV  
547 and cervical cancer. *Bull World Health Organ*. 2020;98(9):615–24.
- 548 23. Søfteland S, Sebitloane MH, Taylor M, Roald BB, Holmen S,  
549 Galappaththi-Arachchige HN, et al. A systematic review of handheld tools in lieu of  
550 colposcopy for cervical neoplasia and female genital schistosomiasis. *Int J Gynecol*  
551 *Obstet* [Internet]. 2021 Feb 12 [cited 2021 Feb 9];153(2):190–9. Available from:  
552 <https://onlinelibrary.wiley.com/doi/10.1002/ijgo.13538>
- 553 24. Norseth HM, Ndhlovu PD, Kleppa E, Randrianasolo BS, Jourdan PM, Roald B, et al.  
554 The colposcopic atlas of schistosomiasis in the lower female genital tract based on  
555 studies in Malawi, Zimbabwe, Madagascar and South Africa. *PLoS Neglected Trop*  
556 *Dis* [Internet]. 2014 Nov;8(11):e3229 (1-17). Available from:  
557 <http://europepmc.org/abstract/med/25412334>
- 558 25. Mbabazi PS, Vwalika B, Randrianasolo BS, Roald B, Ledzinski D, Olowookorun F, et  
559 al. World Health Organisation Female genital schistosomiasis. A pocket atlas for  
560 clinical health-care professionals [Internet]. Vol. 2015, WHO/HTM/NTD/2015.4.

- 561 Geneva: WHO; 2015. 1–49 p. Available from:  
562 [http://apps.who.int/iris/bitstream/10665/180863/1/9789241509299\\_eng.pdf](http://apps.who.int/iris/bitstream/10665/180863/1/9789241509299_eng.pdf)
- 563 26. Kjetland EF, Kurewa EN, Ndhlovu PD, Midzi N, Gwanzura L, Mason PR, et al.  
564 Female genital schistosomiasis - a differential diagnosis to sexually transmitted  
565 disease: Genital itch and vaginal discharge as indicators of genital *S. haematobium*  
566 morbidity in a cross-sectional study in endemic rural Zimbabwe. *Trop Med Int Heal*.  
567 2008;13(12):1509–17.
- 568 27. Randjelovic A, Frønæs SG, Munsami M, Kvalsvig JD, Zulu SG, Gagai S, et al. A  
569 study of hurdles in mass treatment of schistosomiasis in KwaZulu-Natal, South Africa.  
570 *South African Fam Pract* [Internet]. 2015 [cited 2019 Jun 3];57(2):57–61. Available  
571 from:  
572 <https://www.tandfonline.com/action/journalInformation?journalCode=ojfp20><http://dx.doi.org/10.1080/20786190.2014.978121>
- 573 28. Berge ST, Kabatereine NB, Gundersen SG, Taylor M, Kvalsvig JD, Mkhize-  
574 Kwitshana Z, et al. Generic praziquantel in South Africa: The necessity for policy  
575 change to avail cheap, safe and efficacious schistosomiasis drugs to the poor, rural  
576 population. *South Afr J Epidemiol Infect* [Internet]. 2011 [cited 2013 Jan  
577 26];26(1):22–5. Available from: <http://sajei.co.za/index.php/SAJEI/article/view/302>
- 578 29. National Department of Health. Schistosomiasis Mass Drug Administration Plan.  
579 National Department of Health, South Africa; 2023. 1–31 p.
- 580 30. Galappaththi-Arachchige HN, Holmen S, Koukounari A, Kleppa E, Pillay P,  
581 Sebitloane M, et al. Evaluating diagnostic indicators of urogenital *Schistosoma*  
582 *haematobium* infection in young women: A cross sectional study in rural South Africa.  
583 *PLoS One*. 2018;13(2):1–15.
- 584 31. Republic of South Africa. Children’s Act, 2005. Government Gazette, 28944 South  
585 Africa: Government Gazette; 2006 p. 48.
- 586 32. Nguyen VK, Eaton JW. Trends and country-level variation in age at first sex in sub-  
587 Saharan Africa among birth cohorts entering adulthood between 1985 and 2020. *BMC*  
588 *Public Health* [Internet]. 2022;22(1):1–11. Available from:  
589 <https://doi.org/10.1186/s12889-022-13451-y>
- 590 33. Chartsbin. No Title [Internet]. [cited 2023 Jan 18]. Available from:  
591 <http://chartsbin.com/view/xxj>
- 592 34. Mkasi L, Rafudeen A. Debating Virginity-testing Cultural Practices in South Africa: A  
593 Taylorian Reflection. *J Study Relig* [Internet]. 2016;29(2016):118–33. Available from:  
594 <http://www.scielo.org.za/pdf/jsr/v29n2/07.pdf>
- 595 35. Durojaye E. The human rights implications of virginity testing in South Africa. *Int J*  
596 *Discrim Law*. 2016;16(4):228–46.
- 597 36. Department of Basic Education. School Masterlist Data [Internet]. March 2017.  
598 Quarter 4 of 2016. Pretoria; 2017. Available from:  
599 <https://www.education.gov.za/Programmes/EMIS/EMISDownloads.aspx>
- 600 37. Livingston M, Pillay P, Zulu SG, Sandvik L, Kvalsvig JD, Gagai S, et al. Mapping  
601 *Schistosoma haematobium* for novel interventions against Female Genital  
602 Schistosomiasis and associated HIV risk in KwaZulu-Natal, South Africa. *Am J Trop*  
603 *Med Hyg*. 2021;104(6):2055–2064.
- 604 38. National Department of Health. Elimination of Schistosomiasis and Soil Transmitted  
605 Helminths as Public Health Problems in South Africa. 2010. p. 1–48.
- 606 39. Kleppa E, Ramsuran V, Zulu S, Karlsen GH, Bere A, Passmore J-A, et al. Effect of  
607 Female Genital Schistosomiasis and anti- schistosomal treatment on monocytes, CD4+  
608 T-cells and CCR5 expression in the female genital tract. *PLoS One* [Internet].  
609 2014;9(6):e98593 (1-9). Available from: <http://europepmc.org/abstract/med/24896815>
- 610 40. Kleppa E, Klinge KF, Galaphaththi-Arachchige HN, Holmen SD, Lillebø K, Onsrud  
611 M, et al. *Schistosoma haematobium* Infection and CD4+ T-cell levels: A cross-  
612 sectional study of young South African women. *PLoS One*. 2015;10(3):1–9.
- 613

- 614 41. Kleppa E, Holmen SD, Lillebø K, Kjetland EF, Gundersen SG, Taylor M, et al.  
615 Cervical ectopy: associations with sexually transmitted infections and HIV. A cross-  
616 sectional study of high school students in rural South Africa. *Sex Transm Infect.*  
617 2015;91:124–9.
- 618 42. Nemungadi TG, Furumele TE, Gugerty MK, Djirmay AG, Naidoo S, Kjetland EF.  
619 Establishing and Integrating a Female Genital Schistosomiasis Control Programme  
620 into the Existing Health Care System. *Trop Med Infect Dis* 2022, Vol 7, Page 382  
621 [Internet]. 2022 Nov 16 [cited 2022 Nov 21];7(11):382. Available from:  
622 <https://www.mdpi.com/2414-6366/7/11/382/htm>
- 623 43. South African National Department of Health. Regular treatment of school-going  
624 children for soil-transmitted helminth infections and Bilharzia: Policy and  
625 implementation guidelines. Pretoria, South Africa: The South African National  
626 Department of Health; 2008 p. 38.
- 627 44. van Bogaert L. Case of invasive adenocarcinoma of the cervix in a human  
628 immunodeficiency virus and schistosome co-infected patient. *South African J*  
629 *Gynaecol Oncol.* 2014;6(1):5–6.
- 630 45. Kjetland EF, Mduluzi T, Ndhlovu PD, Gomo E, Gwanzura L, Midzi N, et al. Genital  
631 schistosomiasis in women: a clinical 12-month in vivo study following treatment with  
632 praziquantel. *Trans R Soc Trop Med Hyg* [Internet]. 2006;100(8):740–52. Available  
633 from: <http://www.ncbi.nlm.nih.gov/pubmed/16406034>
- 634 46. Downs JA, Kabangila R, Verweij JJ, Jaka H, Peck RN, Kalluvya SE, et al. Detectable  
635 urogenital schistosome DNA and cervical abnormalities 6 months after single-dose  
636 praziquantel in women with *Schistosoma haematobium* infection. *Trop Med Int Heal*  
637 [Internet]. 2013/08/14. 2013;18(9):1090–6. Available from:  
638 <http://www.ncbi.nlm.nih.gov/pubmed/23937701>
- 639 47. van Bogaert LJ. Schistosomiasis - an endemic but neglected tropical disease in  
640 Limpopo. Vol. 100, *South African Medical Journal.* 2010. p. 788–9.
- 641 48. Feldmeier H, Poggensee G, Krantz I. A synoptic inventory of needs for research on  
642 women and tropical parasitic diseases. II. Gender-related biases in the diagnosis and  
643 morbidity assessment of schistosomiasis in women. *Acta Trop* [Internet]. 1993/11/01.  
644 1993 Nov;55(3):139–69. Available from:  
645 <http://www.ncbi.nlm.nih.gov/pubmed/7903838>
- 646 49. Kukula VA, MacPherson EE, Tsey IH, Stothard JR, Theobald S, Gyapong M. A major  
647 hurdle in the elimination of urogenital schistosomiasis revealed: Identifying key gaps  
648 in knowledge and understanding of female genital schistosomiasis within communities  
649 and local health workers. Hsieh MH, editor. *PLoS Negl Trop Dis.* 2018  
650 Mar;13(3):e0007207.
- 651 50. Bland KG, Gelfand M. The effects of schistosomiasis on the cervix uteri in the African  
652 female. *J Obstet Gynaecol Br Commonw* [Internet]. 1970/11/01. 1970;77(11):1127–  
653 31. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/5493619>
- 654 51. Poggensee G, Kiwelu I, Saria M, Richter J, Krantz I, Feldmeier H. Schistosomiasis of  
655 the lower reproductive tract without egg excretion in urine. *Am J Trop Med Hyg*  
656 [Internet]. 1998;59(5):782–3. Available from: [http://www.ncbi.nlm.nih.gov/htbin-](http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&dopt=r&uid=0009840597)  
657 [post/Entrez/query?db=m&form=6&dopt=r&uid=0009840597](http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&dopt=r&uid=0009840597)
- 658  
659